Corcept Loses Patent Appeal for Korlym, Shares Plunge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy CORT?
Source: stocktwits
- Patent Litigation Outcome: The U.S. Court of Appeals upheld the New Jersey district court's ruling that Corcept failed to prove patent infringement, resulting in significant legal challenges that could impact the company's competitive position in the market.
- Stock Price Reaction: Following the ruling, Corcept's (CORT) shares plummeted by 15%, reflecting investor concerns about the company's future, especially as its Korlym product faces generic competition.
- Market Dynamics: While Corcept's stock declined, Teva Pharmaceuticals (TEVA) saw a slight increase in its share price, indicating a positive market reaction to Teva's victory in the patent dispute, which may enhance its market share.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around CORT stock shifted from 'bearish' to 'bullish' over the past 24 hours, with message volume increasing from 'extremely low' to 'high', indicating investor expectations for a potential rebound.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 40.310
Low
50.00
Averages
91.00
High
121.00
Current: 40.310
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- Lawsuit Background: The lawsuit, filed by the Allegheny County Employees' Retirement System, targets all investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, seeking to recover losses incurred during this period.
- Disclosure Failures: The complaint alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, Relacorilant, by failing to disclose critical information reportedly communicated by the FDA, which has led to significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to assist in the investigation, as the new SEC Whistleblower program offers rewards of up to 30% of any successful recovery, thereby enhancing the case's potential for success.
See More
Multiple Companies Face Class Action Lawsuits
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. faces a class action lawsuit for materially misstated financial statements and inadequate internal controls during the period from August 2024 to February 2026, which severely undermines investor confidence and could negatively impact its stock performance.
- PayPal Lawsuit Details: PayPal Holdings, Inc. is accused in a class action lawsuit from February 2025 to February 2026 of overstating its business execution capabilities and dismissing competitive concerns, leading to a decline in investor trust and potential adverse effects on its market share.
- NuScale Lawsuit Background: NuScale Power Corporation is facing a class action lawsuit for failing to disclose significant risks associated with its nuclear projects during the period from May 2025 to November 2025, which could jeopardize its commercialization strategy and affect future financing and project timelines.
- Corcept Lawsuit Issues: Corcept Therapeutics Incorporated is under scrutiny in a class action lawsuit from October 2024 to January 2026 for not meeting FDA requirements regarding the effectiveness assessment of its drug, which may lead to significant review challenges for its new drug application and impact the company's future competitiveness.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the securities class action against Corcept, which involves stock purchases made between October 31, 2024, and December 30, 2025, highlighting investor concerns over the company's disclosure practices.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 to $34.80 after the FDA rejected its new drug application, indicating a significant loss of investor confidence in the company's future prospects.
- Legal Allegations Context: The lawsuit alleges that Corcept and its executives failed to disclose material information during the class period, violating federal securities laws, which suggests a potential breach of fiduciary duty that could lead to substantial investor losses.
- Law Firm's Role: Kahn Swick & Foti, LLC, representing the plaintiffs, specializes in recovering losses for investors due to corporate fraud or misconduct, demonstrating its expertise and influence in the securities litigation landscape.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026, urging investors to contact the firm promptly to protect their rights.
- False Statements Allegation: Throughout the Class Period from 2024 to 2025, Corcept is accused of failing to disclose significant FDA concerns regarding the effectiveness data of its lead drug candidate, Relacorilant, resulting in substantial investor losses.
- Stock Price Crash: On December 31, 2025, Corcept revealed it received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day.
- Information Gap Issue: The heart of the case lies in the significant discrepancy between the information the company publicly disclosed and what the FDA reportedly communicated privately, leading to investor misjudgments about the company's prospects and impacting market confidence.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm will operate on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the support for its drug relacorilant's New Drug Application (NDA) to the FDA, claiming strong clinical trial backing, while the FDA had raised concerns about the adequacy of clinical evidence, exposing investors to potential losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
See More
Corcept Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Corcept Therapeutics, alleging securities fraud and other unlawful business practices, with investors required to apply as Lead Plaintiff by April 21, 2026.
- FDA's Negative Response: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, which requested additional evidence of effectiveness for relacorilant, indicating significant concerns regarding the drug's safety and efficacy from the regulatory body.
- Stock Price Plunge: Following the FDA's announcement, Corcept's stock price plummeted by $35.40, a 50.4% drop, closing at $34.80 per share, reflecting the market's pessimistic outlook on the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent class action law firm specializing in securities and antitrust litigation, with a long history of recovering multimillion-dollar damages for victims, demonstrating its strong capabilities in the legal field.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- Lawsuit Background: The lawsuit, filed by the Allegheny County Employees' Retirement System, targets all investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, seeking to recover losses incurred during this period.
- Disclosure Failures: The complaint alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, Relacorilant, by failing to disclose critical information reportedly communicated by the FDA, which has led to significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to assist in the investigation, as the new SEC Whistleblower program offers rewards of up to 30% of any successful recovery, thereby enhancing the case's potential for success.
See More
Multiple Companies Face Class Action Lawsuits
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. faces a class action lawsuit for materially misstated financial statements and inadequate internal controls during the period from August 2024 to February 2026, which severely undermines investor confidence and could negatively impact its stock performance.
- PayPal Lawsuit Details: PayPal Holdings, Inc. is accused in a class action lawsuit from February 2025 to February 2026 of overstating its business execution capabilities and dismissing competitive concerns, leading to a decline in investor trust and potential adverse effects on its market share.
- NuScale Lawsuit Background: NuScale Power Corporation is facing a class action lawsuit for failing to disclose significant risks associated with its nuclear projects during the period from May 2025 to November 2025, which could jeopardize its commercialization strategy and affect future financing and project timelines.
- Corcept Lawsuit Issues: Corcept Therapeutics Incorporated is under scrutiny in a class action lawsuit from October 2024 to January 2026 for not meeting FDA requirements regarding the effectiveness assessment of its drug, which may lead to significant review challenges for its new drug application and impact the company's future competitiveness.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the securities class action against Corcept, which involves stock purchases made between October 31, 2024, and December 30, 2025, highlighting investor concerns over the company's disclosure practices.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 to $34.80 after the FDA rejected its new drug application, indicating a significant loss of investor confidence in the company's future prospects.
- Legal Allegations Context: The lawsuit alleges that Corcept and its executives failed to disclose material information during the class period, violating federal securities laws, which suggests a potential breach of fiduciary duty that could lead to substantial investor losses.
- Law Firm's Role: Kahn Swick & Foti, LLC, representing the plaintiffs, specializes in recovering losses for investors due to corporate fraud or misconduct, demonstrating its expertise and influence in the securities litigation landscape.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026, urging investors to contact the firm promptly to protect their rights.
- False Statements Allegation: Throughout the Class Period from 2024 to 2025, Corcept is accused of failing to disclose significant FDA concerns regarding the effectiveness data of its lead drug candidate, Relacorilant, resulting in substantial investor losses.
- Stock Price Crash: On December 31, 2025, Corcept revealed it received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day.
- Information Gap Issue: The heart of the case lies in the significant discrepancy between the information the company publicly disclosed and what the FDA reportedly communicated privately, leading to investor misjudgments about the company's prospects and impacting market confidence.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm will operate on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the support for its drug relacorilant's New Drug Application (NDA) to the FDA, claiming strong clinical trial backing, while the FDA had raised concerns about the adequacy of clinical evidence, exposing investors to potential losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
See More
Corcept Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Corcept Therapeutics, alleging securities fraud and other unlawful business practices, with investors required to apply as Lead Plaintiff by April 21, 2026.
- FDA's Negative Response: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, which requested additional evidence of effectiveness for relacorilant, indicating significant concerns regarding the drug's safety and efficacy from the regulatory body.
- Stock Price Plunge: Following the FDA's announcement, Corcept's stock price plummeted by $35.40, a 50.4% drop, closing at $34.80 per share, reflecting the market's pessimistic outlook on the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent class action law firm specializing in securities and antitrust litigation, with a long history of recovering multimillion-dollar damages for victims, demonstrating its strong capabilities in the legal field.
See More
